Published in FDA Law Weekly, January 18th, 2007
MuGard is Access' proprietary oral rinse product for the management of oral mucositis, the debilitating side-effect which afflicts more than 40% of cancer patients undergoing radiation and chemotherapy.
There is currently no well-accepted treatment for mucositis, and the company believes that MuGard should be a valuable supportive care option for cancer patients. The estimated size of the market for this indication in the U.S. exceeds $1 billion. The company is actively seeking marketing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.